Chordoma Clinical Trials 2024

Chordoma Clinical Trials 2024

Chordoma research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in chordoma clinical trials today.

Trials With No Placebo

View More Related Trials

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to chordoma

What are the top hospitals conducting chordoma research?

When it comes to pioneering clinical trials in the realm of chordoma research, several prominent hospitals are leading the charge. In Boston's medical landscape, Massachusetts General Hospital stands out with five ongoing chordoma trials, contributing to a total of nine conducted studies since their first trial was recorded in 1999. The Dana-Farber Cancer Institute, another renowned facility in the city, is currently conducting three active chordoma trials while having completed four previous investigations since their inaugural trial in 1999 as well. Not to be overlooked is New york City's Memorial Sloan Kettering Cancer Center, where researchers are actively exploring this rare bone cancer through three ongoing clinical trials and have previously carried out four additional studies following their initial involvement with chordoma research also back in 1999.

Boston Children's Hospital plays an important role too by delving into two current chordoma trials while holding a record for two prior investigations; they commenced their journey towards understanding this condition only last year in 2020. Meanwhile, Mayo Clinic - Jacksonville contributes significantly from Florida with its two active chordoma trials and two historically held investigations; theirs can be traced back six years ago when they initiated their first trial specifically targeting this disease.

These esteemed hospitals demonstrate not only dedication but also remarkable progress toward unraveling the complexities of chordoma—providing hope for those affected by this rare form of bone cancer. Together, these institutions offer a beacon of optimism that every step forward brings us closer to improved treatments and ultimately finding a cure for patients battling this challenging condition across the nation

Which are the best cities for chordoma clinical trials?

Boston, Massachusetts; Los Angeles, California; and Anchorage, Alaska are recognized as leading cities for chordoma clinical trials. Boston takes the lead with 12 active studies focused on investigating treatments like Tazemetostat, Nivolumab, and TAEK-VAC-HerBy. Los Angeles follows closely behind with 9 ongoing trials studying options such as Nivolumab, BCA101, and Arm B (atezolizumab, tiragolumab). Anchorage also demonstrates promising research efforts with 8 active trials primarily exploring the use of Nivolumab in treatment approaches. These cities offer individuals diagnosed with chordoma invaluable access to cutting-edge clinical trials that drive advancements in care and provide hope for improved outcomes.

Which are the top treatments for chordoma being explored in clinical trials?

Exciting advancements are taking place in clinical trials for chordoma, with several promising treatments at the forefront. Nivolumab leads the pack with three ongoing trials and a total of six all-time chordoma trials since its debut in 2017. Tazemetostat follows closely behind, showing potential in two active and two all-time chordoma studies since 2015. Cetuximab, TAEK-VAC-HerBy, and FAZ053 also show promise, each being explored in one active trial along with their respective all-time chordoma trial records. As researchers delve deeper into these innovative treatments, hope grows brighter for patients battling this rare cancerous tumor originating from bone or soft tissue.

What are the most recent clinical trials for chordoma?

Recent clinical trials offer hope for patients with chordoma, a rare type of cancer that develops in the bones of the skull and spine. One promising study is investigating the effectiveness of tazemetostat, which has shown potential in both Phase 1 and Phase 2 trials. Another trial focuses on Arm B, combining atezolizumab and tiragolumab to explore their impact on chordoma treatment. Additionally, cetuximab and nivolumab have demonstrated encouraging results in separate Phase 2 studies. These advancements provide new possibilities for improving outcomes and quality of life for individuals affected by this challenging disease.

What chordoma clinical trials were recently completed?

Recently completed clinical trials for chordoma have made significant strides in advancing treatment options for this challenging condition. In September 2019, the John Wayne Cancer Institute concluded a trial investigating the efficacy of Pemetrexed. Additionally, in October 2018, Bavarian Nordic completed a trial evaluating BN-Brachyury in combination with radiation therapy. Another noteworthy study was conducted by Intensity Therapeutics, Inc., who wrapped up their investigation into INT230-6 in February 2017. These recent advancements offer hope and highlight the dedication of researchers to find innovative solutions for patients with chordoma.